ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

High-Dose Vitamin D With Docetaxel In Testing For Advanced Prostate Cancer

September 27, 2002

In Brief: Ford Decides Against Asking For Recision Of NCI Funds After Congress Overrides Verto

October 8, 1976

Separation Will Make Interaction Easier; AACR President Says

June 26, 1992

FDA Approves Abraxane And Alimta for NSCLC

October 26, 2012

Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough?

December 14, 2007

NCI Gets Concept Approval for New Communications Network

May 27, 1988